id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6003-0007,FDA,FDA-2017-E-6003,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:20:49Z,,0,0,0900006483f86854
FDA-2017-E-6003-0006,FDA,FDA-2017-E-6003,"Determination of Regulatory Review Period for Purposes of Patent
Extension; PARSABIV",Notice,Determinations,2018-12-28T05:00:00Z,2018,12,2018-12-28T05:00:00Z,2019-02-27T04:59:59Z,2018-12-31T21:10:48Z,2018-28221,0,0,09000064839cbe98
FDA-2017-E-6003-0005,FDA,FDA-2017-E-6003,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:44:04Z,,0,0,09000064839c0685
FDA-2017-E-6003-0004,FDA,FDA-2017-E-6003,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T14:24:34Z,,0,0,090000648378b7a2
FDA-2017-E-6003-0003,FDA,FDA-2017-E-6003,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-17T04:00:00Z,2017,10,2017-10-17T04:00:00Z,,2017-10-17T20:12:22Z,,0,0,0900006482bd6144
FDA-2017-E-6003-0002,FDA,FDA-2017-E-6003,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2017-10-03T04:00:00Z,2017,10,2017-10-03T04:00:00Z,,2017-10-03T16:12:22Z,,0,0,0900006482b94b98
FDA-2017-E-6003-0001,FDA,FDA-2017-E-6003,Patent Extension Application from McDermott Will & Emerly LLP (on behalf of KAI Pharmaceuticals Inc),Other,Application,2017-10-03T04:00:00Z,2017,10,2017-10-03T04:00:00Z,,2017-10-03T16:06:10Z,,0,0,0900006482b943d8